ZimVie Stock Soars 121.92% on ARCHIMED Acquisition Deal

On July 21, 2025, ZimVie's stock surged by 121.92% in pre-market trading, driven by the announcement of a definitive agreement to be acquired by ARCHIMED for $19.00 per share in cash.

ZimVie, a global leader in the dental implant market, has entered into a definitive agreement to be acquired by ARCHIMED, a healthcare-focused investment firm. The all-cash transaction values ZimVie at approximately $730 million, representing a 99% premium to the company's 90-day volume-weighted average price of $9.57 per share. The acquisition, unanimously approved by ZimVie's Board of Directors, is expected to close by year-end 2025, subject to stockholder and regulatory approvals.

Under the terms of the agreement, ZimVie shareholders will receive $19.00 per share in cash. The transaction includes a 40-day "go-shop" period through August 29, 2025, during which ZimVie may solicit alternative proposals. Upon completion, ZimVie will become a privately held company and delist from NASDAQ.

This acquisition by ARCHIMED at a 99% premium offers shareholders immediate significant value while addressing potential growth challenges. The deal allows ZimVie to focus on longer-term innovation and market expansion under ARCHIMED's healthcare-focused ownership, potentially benefiting from strategic investment and industry expertise.